Patents by Inventor Trixi Brandl

Trixi Brandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120231998
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Patent number: 8232286
    Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Breitfelder, Udo Maier, Trixi Brandl, Christoph Hoenke, Matthias Grauert, Alexander Pautsch, Matthias Hoffmann, Frank Kalkbrenner, Anne T. Joergensen, Gerhard Schaenze, Stefan Peters, Frank Buettner, Eckhart Bauer
  • Patent number: 8211932
    Abstract: The present application describes organic compounds of the Formula I that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 3, 2012
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Patent number: 8193188
    Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: June 5, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
  • Publication number: 20120035168
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 9, 2012
    Applicant: NOVARTIS AG
    Inventors: Trixi BRANDL, Stefanie FLOHR, Sebastian KOPEC, Julie LACHAL, Christian MARKERT, Kenji NAMOTO, Perle NGANGA, Bernard PIRARD, Martin RENATUS, Richard SEDRANI, Thomas ZOLLER
  • Publication number: 20110182850
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 7, 2010
    Publication date: July 28, 2011
    Inventors: Trixi BRANDL, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Publication number: 20100331243
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 10, 2010
    Publication date: December 30, 2010
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Patent number: 7825152
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 2, 2010
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Publication number: 20100260709
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 7, 2010
    Publication date: October 14, 2010
    Inventors: Trixi BRANDL, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Publication number: 20100204211
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 22, 2009
    Publication date: August 12, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Gerald Juergen ROTH, Armin HECKEL, Nveed CHAUDHARY, Trixi BRANDL, Georg DAHMANN, Matthias GRAUERT
  • Patent number: 7750152
    Abstract: Disclosed are dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the pharmaceutical compositions, isomers, intermediates thereof and processes for preparing these dihydropteridinones. The compounds are useful the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: July 6, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Matthias Hoffman, Matthias Grauert, Trixi Brandl, Steffen Breitfelder, Christian Eickmeier, Martin Steegmaier, Gisela Schnapp, Anke Baum, Jens Jurgen Quant, Flavio Solca, Florian Colbatzky
  • Publication number: 20100145041
    Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Trixi BRANDL, Udo MAIER, Matthias HOFFMANN, Stefan SCHEUERER, Anne T. JOERGENSEN, Alexander PAUTSCH, Steffen BREITFELDER, Matthias GRAUERT, Christoph HOENKE, Klaus ERB, Michael PIEPER, Ingo PRAGST
  • Publication number: 20100113414
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo BETZEMEIER, Trixi BRANDL, Steffen BREITFELDER, Ralph BRUECKNER, Thomas GERSTBERGER, Michael GMACHL, Matthias GRAUERT, Frank HILBERG, Christoph HOENKE, Matthias HOFFMANN, Maria IMPAGNATIELLO, Dirk KESSLER, Christian KLEIN, Bernd KRIST, Udo MAIER, Darryl McCONNELL, Charlotte REITHER, Stefan SCHEUERER, Andreas SCHOOP, Norbert SCHWEIFER, Oliver SIMON, Martin STEEGMAIER, Steffen STEURER, Irene WAIZENEGGER, Ulrike WEYER-CZERNILOFSKY, Andreas ZOEPHEL
  • Publication number: 20100099680
    Abstract: New compounds of Formula (1) are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Application
    Filed: January 28, 2008
    Publication date: April 22, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Riccardo Giovannini, Sara Frattini, Trixi Brandl, Steffen Breitfelder, Enzo Cereda, Matthias Grauert, Matthias Hoffmann, Anne T. Joergensen, Udo Maier, Alexander Pautsch, Monica Quai, Stefan Scheuerer
  • Patent number: 7691888
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 6, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Patent number: 7691868
    Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: April 6, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Trixi Brandl, Udo Maier, Matthias Hoffmann, Stefan Scheuerer, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Christoph Hoenke, Klaus Erb, Michael Pieper, Ingo Pragst
  • Publication number: 20100029642
    Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
    Type: Application
    Filed: October 14, 2009
    Publication date: February 4, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias HOFFMANN, Matthias GRAUERT, Trixi BRANDL, Martin STEEGMAIER, Rudolf HAUPTMANN
  • Patent number: 7625899
    Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: December 1, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
  • Publication number: 20090156554
    Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Application
    Filed: February 5, 2009
    Publication date: June 18, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Steffen BREITFELDER, Udo MAIER, Trixi BRANDL, Christoph HOENKE, Matthias GRAUERT, Alexander PAUTSCH, Matthias HOFFMANN, Frank KALKBRENNER, Anne T. JOERGENSEN, Gerhard SCHAENZLE, Stefan PETERS, Frank BUETTNER, Eckhart BAUER